AU2916302A - Aqueous immunologic adjuvant compositions of monophosphoryl lipid - Google Patents

Description

Regulation 3.2

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION r DIVISIONAL PATENT

APPLICANT:

Invention Title: CORIXA CORPORATION Aqueous immunologic adjuvant compositions of monophosphoryl lipid A The following statement is a full description of this invention, including the best method of performing it known to me: M:\CommonWord97\10001-10500\1 0408cor\20020328.doc 'WO 98/43670 PCT/US98/06528 1

DESCRIPTION

Aqueous Immunologic Adjuvant Compositions of Monophosphoryl Lipid A Cross-Reference to a Related Application This application is a continuation-in-part of co-pending application Serial No.

08/831,073, filed April 1, 1997.

Background of the Invention The compounds monophosphoryl lipid A (MLA) and 3-O-deacylated I monophosphoryl lipid A (3D-MLA) are attenuated derivatives of the lipid A component of bacterial lipopolysaccharide (LPS). LPS and lipid A are potent immunostimulants inducing both a humoral antibody response and a cell-mediated immune response in patients administered the compounds. Lipid A and LPS however 15 can also display toxic side-effects such as pyrogenicity and local Shwarzman reactions.

MLA and 3D-MLA are lipid A-like molecules that have been modified to attenuate the toxicity of LPS.

Like lipid A, the MLA and 3D-MLA molecules have a sugar backbone onto which long chain fatty acids are attached. The backbone is comprised of two six carbon sugar rings in glycosidic linkage. MLA and 3D-MLA are phosphorylated at the 4 position. Five to eight long chain fatty acids (12-14 carbons) are attached to the sugar backbone making MLA and 3D-MLA very hydrophobic molecules which are not readily water soluble.

The attenuated lipid A derivatives (ALDs) MLA and 3D-MLA are used as immunologic adjuvants in prophylactic vaccines for infectious disease and therapeutic vaccines for the treatment of cancerous tumors and chronic infections. Antigen preparations included in most vaccines are often complicated mixtures of water-soluble proteins making it difficult to formulate the water insoluble adjuvant in a water based vaccine. Therefore, MLA and 3D-MLA must be first mixed with solvents before they are added to the antigen preparation. However, the presence of solvents can further complicate the formulation of the vaccine, and in some cases can reduce the efficiency .WO 98/43670 PCT/US98/06528 2 of its components. Further, solvents can irritate mucosal surfaces or cause inflammation at an injection site. A simple formulation of MLA or 3D-MLA containing no interfering co-solvents would allow maximum benefits to be derived from both the adjuvant and the antigen in a vaccine composition. The instant invention satisfies this need.

Summary of the Invention The subject invention involves an aqueous formulation of an attenuated lipid A derivative (ALD) and a surfactant and methods for its preparation. Attenuated lipid A derivatives useful according to the subject invention include monophosphoryl lipid A (MLA) and 3-O-deacylated monophosphoryl lipid A (3D-MLA). Aqueous formulations of MLA (MLA/AF) or 3D-MLA (3D-MLA/AF) eliminate the need for undesirable solvents or a co-solvent system for vaccine preparation. The invention provides a stable aqueous composition of the ALD and a surfactant which when S 15 administered to mice with an antigen, enhances the cellular and humoral immune response of the animal to that antigen. Surprisingly, the aqueous formulation of the S. present invention induces high levels of serum and mucosal secreted IgA in immunized animals when administered intranasally. An embodiment of the claimed aqueous composition comprises a MLA or 3D-MLA to surfactant molar ratio of about 4:1 and 20 has a particle size of approximately 50-70 nm. 1, 2 -Dipalmitoyl-sn-glycero-3phosphocholine (DPPC) is a preferred surfactant.

A method of preparing the aqueous composition is disclosed. In one embodiment the ALD and the surfactant are dissolved and uniformly admixed in ethanol. The ethanol is then evaporated leaving a film. Water is added to the film.

The ALD and surfactant are suspended in the water by sonication. The suspension is sonicated until clear. Animals administered the claimed composition with an antigen display enhanced humoral and cellular immune responses to that antigen. Methods for using the composition to enhance these responses are also disclosed and claimed.

-WO 98/43670 PCT/US98/06528 3 Brief Description of the Figures Figure 1 a-d show the antibody titers of mice administered tetanus toxoid (TT) antigen in 3 -O-deacylated monophosphoryl lipid A-aqueous formula (3D-MLA/AF) or tetanus toxoid antigen in saline o. Figure la shows the total IgG antibody titers of mice administered the tetanus toxoid antigen. Figure lb shows the IgG2a antibody titers of mice administered the tetanus toxoid antigen. Figure Ic shows the IgG2b antibody titers of mice administered the tetanus toxoid antigen and Figure Id shows the IgG1 antibody titers for the animals.

Figure 2 shows the T-cell proliferative response in mice immunized with a purified protein derivative. The proliferative response in mice administered tetanus toxoid in 3D-MLA/AF and normal controlso are shown 14 days post primary vaccination.

Detailed Description of the Invention 15 The subject invention involves an aqueous adjuvant formulation of an attenuated lipid A derivative (ALD). The ALD and a surfactant are suspended in :water in a molar ratio of approximately 4:1 and sonicated to yield a suspension having a particle size of approximately 50-70 nm.

In accordance with the present invention, an attenuated lipid A derivative can 20 be formulated into an aqueous composition to provide a potent adjuvant. An attenuated lipid A derivative is a lipid A-like compound which displays the advantageous immunostimulatory properties of lipid A yet exhibits less of the adverse side affects of that compound. For example, monophosphoryl lipid A (MLA) and deacylated monophosphoryl lipid A (3D-MLA) are ALDs that are potent immunostimulants but are surprisingly less toxic than lipid A. Both MLA and 3D- MLA can be used in the compositions of the subject invention and are known and need not be described in detail herein. See for example U.S. Patent No. 4,436,727 issued March 13, 1984, assigned to Ribi ImmunoChem Research, Inc., which discloses monophosphoryl lipid A and its manufacture. U.S. Patent No. 4,912,094 and reexamination certificate B1 4,912,094 to Myers, et al., also assigned to Ribi ImmunoChem Research, Inc., embodies 3-O-deacylated monophosphoryl lipid A and a I WO 98/43670 PCT/US98/06528 4 method for.its. manufacture. Disclosures of each of these patents with respect to MLA and 3D-MLA are incorporated herein by reference.

Without going into the details of the prior incorporated by reference patents, monophosphoryl lipid A (MLA) as used herein is derived from lipid A, a component of enterobacterial lipopolysaccharides (LPS), a potent but highly toxic immune system modulator. Edgar Ribi and his associates achieved the production of monophosphoryl lipid A (MLA) referred to originally as refined detoxified endotoxin. MLA is produced by refluxing an endotoxin extract (LPS or lipid A) obtained from heptoseless mutants of gram-negative bacteria in mineral acid solutions of moderate strength 0.1 N HCI) for a period of approximately 30 minutes. This treatment results in the loss of the phosphate moiety at position 1 of the reducing end glucosamine.

i Coincidentally, the core carbohydrate is removed from the 6 position of the non-reducing glucosamine during this treatment. The resulting product (MLA) *o .exhibits considerably attenuated levels of the endotoxic activities normally associated 15 with the endotoxin starting material, such as pyrogenicity, local Shwarzman reactivity, and toxicity as evaluated in the chick embryo 50% lethal dose assay (CELDso).

However, it unexpectedly retains the functionality of lipid A and LPS as an immunomodulator.

Another attenuated lipid A derivative which may be utilized in the practice of 20 the present invention is referred to as 3-O-deacylated monophosphoryl lipid A (3D- MLA). 3D-MLA is known as set forth in U.S. patent No. 4,912,094, reexamination certificate B1 4,912,094 (the '094 patent), and differs from MLA in that there is selectively removed from the MLA molecule the P-hydroxymyristic acyl residue that is ester linked to the reducing-end glucosamine at position 3 under conditions that do not adversely affect the other groups. 3-0-deacylated monophosphoryl lipid A is available from Ribi ImmunoChem Research, Inc., Hamilton, Montana 59840.

The MLA and 3D-MLA molecules are a composite or mixture of a number of fatty acid substitution patterns, heptaacyl, hexaacyl, pentaacyl, etc., with varying fatty acid chain lengths. Thus, these various forms of MLA and 3D-MLA are encompassed by this invention. Further, mixtures of forms of a compound as well as individual compounds produced by synthetic or semisynthetic means are encompassed I -WO 98/43670 PCT/US98/06528 by-th'-i-nvention. The lipid A backbone that is illustrated in the 094 patent corresponds to the product that is obtained by 3-deacylation ofheptaacyl lipid A from S. minnesota R 595. Other fatty acid substitution patterns are encompassed by this disclosure; the essential feature is that the material be The modified 3D-MLA utilized in the present invention is prepared by subjecting MLA to alkaline hydrolysis under conditions that result in the loss of but a single fatty acid from position 3 of the lipid A backbone. P-hydroxymyristic fatty acid at position 3 is unusually labile in alkaline media. It requires only very mild alkaline treatment to completely 3-deacylate lipid A. The other ester linkages in lipid A require somewhat stronger conditions before hydrolysis will occur so that it is possible to selectively deacylate these materials at position 3 without significantly affecting the rest o: of the molecule. The reason for the unusual sensitivity to alkaline media of the esterlinked P-hydroxymyristic fatty acid at position 3 is not known at this time.

Although alkaline hydrolysis procedures are known, it is important to choose 15 conditions that do not cause further hydrolysis beyond the ester linkage to the Phydroxymyristic at position 3. In general the hydrolysis can be carried out in aqueous or organic media. In the latter case, solvents include methanol (alcohols), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), chloroform, dichloromethane, and the like, as well as mixtures thereof. Combinations of water and one or more of the o 20 mentioned organic solvents also can be employed.

The alkaline base can be chosen from among various hydroxides, carbonates, phosphates and amines. Illustrative bases include the inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and the like, and organic bases such as alkyl amines, and include, but are not limited to, diethylamine, triethylamine, and the like.

In aqueous media the pH is typically between approximately 10 and 14 with a pH of about 12 to about 13.5 being the preferred range. The hydrolysis reaction is typically carried out at a temperature of from about 20 C to about 80 C, preferably about 50°C to 60 0 C for a period of about 10 to about 30 minutes. For example, the hydrolysis can be conducted in 3% triethylamine in water at room temperature (22"- C) for a period of 48 hours. The only requirement in the choice of temperature and WO 98/43670 PCT/US98/06528 6 ,Airoeof hydrolysis is that deacylation occurs to remove only the P-hydoxymyristic at position 3.

In practice it has been found that a particularly desirable hydrolysis method involves dissolving lipid A or monophosphoryl lipid A in chloroform:methanol 2:1 saturating this solution with an aqueous buffer consisting of 0.5 M Na 2

CO

3 at pH 10.5, and then flash evaporating the solvent at 45"-50*C under a vacuum or an aspirator (approximately 100 mm Hg). The resulting material is selectively deacylated at position 3. This process can also be carried out with any of the inorganic bases listed above. The addition of a phase transfer catalyst, such as tetrabutyl ammonium bromide, to the organic solution prior to saturation with the aqueous buffer may be desirable in some cases.

In preparing the composition of the subject invention, generally, the attenuated lipid A derivative (ALD) is combined with the surfactant each being dissolved in a solvent. The solvent is evaporated leaving a film. Water is added to the film and the 15 resulting suspension is sonicated while heated until clear. The final suspension has a particle size of approximately 40-150 nm and preferably from about 50 to about nm.

The ALD and surfactant are combined at a molar ratio of about 10 parts ALD to from about 1 part to about 5 parts surfactant. Preferably, the components are 20 combined in a molar ratio of about 4 parts ALD to 1 part surfactant. Surfactants useful according to the subject invention include but are not limited to bile salts, natural phospholipids and sphingolipids. Bile salts such as glycodeoxycholate and deoxycholate are useful as surfactants in the claimed compositions. Other suitable surfactants include sphingolipids such as sphingomyelin and sphingosine and phospholipids such as egg phosphatidylcholine, 1,2-Dimyristoyl-sn-glycero-3phosphoethanolamine, L-a-Phosphatidylethanolamine, and 1,2-Dipalmitoyl-sn-glycero- 3-phosphocholine or mixtures thereof. In a preferred embodiment, the phospholipid 1, 2 -Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) is the surfactant. DPPC is accepted for use in humans and is especially effective when the formulation is administered intranasally.

The ALD and surfactant are dissolved and thoroughly admixed in a solvent.

-WO 98/43670 PCT/US98/06528 7 Aqueous or organic solvents useful according to the subject invention include chloroform, alcohols (eg. ethanol), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and the like, as well as mixtures thereof.

The solvent is evaporated from the mixture of ALD and surfactant leaving a film. Water is added to the film and the resulting suspension is sonicated while heated until clear. It is preferred that the suspension be sonicated in a water bath sonicator.

The water bath temperature can be from 40"C to 80°C and preferably about The suspension can be sonicated for periods of 5 minutes to approximately one hour until clear. Periods of sonication will vary depending upon the volume and concentration of the suspension but can be readily determined by one skilled in the art.

The final suspension has a particle size of approximately 40-150 nm and preferably from about 50 to about 70 nm.

An effective amount of the composition of the subject invention is administered to a warm-blooded animal with an antigen to enhance the immune response of the 15 animal to that antigen. The composition of the subject invention enhances both the humoral immune response of an animal to an antigen as well as the cellular immune response. The amount of antigen administered to elicit the desired response can be readily determined by one skilled in the art and will vary with the type of antigen administered, route of administration and immunization schedules. For example, 0.1 20 gg of tetanus toxoid administered with the claimed composition subcutaneously to a mouse in two immunizations 21 days apart elicits a humoral immune response to that antigen. Administered intranasally, the composition of the subject invention and an antigen stimulate the production of cytotoxic T-lymphocytes. Hepatitis B surface antigen (2.5 ug) administered intranasally at days 0 and 21 in the claimed composition stimulated the production of cytotoxic T-lymphocytes in immunized animals. Further, the composition of the subject invention is particularly effective in eliciting an IgA response in immunized animals when administered intranasally. Mice administered 12.5 pg of tetanus toxoid in an aqueous formulation of monophosphoryl lipid A (3D-MLA/AF) displayed increased IgA titers to that antigen.

An effective amount of the composition of the subject invention is that amount which stimulates or enhances an immune response. For example, an effective amount of the -WO 98/43670 PCT/US98/06528 8 claimed composition can contain from 1 to about 250 micrograms of attenuated lipid A derivative and preferably from about 25 to about 50 micrograms based upon administration to a typical 70 kg adult patient.

The following examples are offered to further illustrate but not limit both the compositions and the method of the present invention. It is to be understood that the mouse models presented herein are representative of warm blooded animals and correlate reasonably with events for other warm blooded animals, including humans.

All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1-Preparation of an Aqueous Formulation of an Attenuated Lipid A Derivative.

An aqueous preparation of 3-O-deacylated monophosphoryl lipid A (3D- 15 MLA/AF) according to the subject invention comprising 1000 gg/ml 3D-MLA (Ribi S. ImmunoChem Research, Inc., Hamilton, Montana 59840), an attenuated form of lipid A from Salmonella minnesota R 595 and 118 pg/ml 1,2 Dipalmitoyl-sn-glycero-3- 9 phosphocholine (DPPC) in Water for Injection was prepared as follows: 9 A solution of DPPC was prepared at a concentration of 4 mg/ml in 20 ethanol and vortexed until clear. A 2.7 ml aliquot of the DPPC solution *o was added to a vial containing 100 mg lyophilized 3D-MLA and swirled gently to wet the 3D-MLA. The ethanol was removed by blowing a stream of filtered nitrogen gently into the vial. Water for Injection (91.7 ml) was added to the vial which was then stoppered, sealed and suspended in a Labline 9303 water bath sonicator. The suspension was sonicated for 10 minutes at 60 C until clear. The resulting aqueous formulation contained particles of 70 nm measured by a PSC 100 Spectrometer from Malvern Instruments and was filter sterilized through a 0.2 gm filter.

WO 98/43670 PCT/US98/06528 9 Example 2-Stimulation of an Antibody Response.

Mice immunized with tetanus toxoid (TT) in the aqueous formulation of the subject invention generated tetanus toxoid specific antibody. The TT-specific total IgG titer and IgG isotypes (2a, 2b, 1) titers were measured by enzyme-linked immunosorbent assay (ELISA) in the sera of mice following immunization.

Female ICR mice were immunized with a dose of vaccine containing 0.1 Pg of tetanus toxoid (TT) 50 Ig 3D-MLA/AF or 0.1 pg TT in saline. 3D-MLA/AF was prepared as in Example 1. The vaccines were administered by subcutaneous injection on days 0 and 21. Serum was collected 14 days post secondary immunization and assayed by standard ELISA techniques to report the relative amounts of tetanus-toxoid specific antibody oflgG,, IgGz and IgG, isotypes as well as total IgG.

Figure 1 shows the tetanus toxoid specific antibody titer generated by 3D- MLA/AF. 3D-MLA/AF when administered with the tetanus toxoid antigen stimulates the production of IgG antibody in immunized animals and in particular actively S 15 stimulates IgG, production.

Example 3-Stimulation of Cellular Proliferation.

Mice primed by immunization with the adjuvant composition of the subject invention and a purified protein derivative (PPD) (tuberculin) exhibited a proliferative 20 response in vitro when spleen cells were treated with that antigen.

Female BALB/c mice were immunized by subcutaneous injection with a dose of vaccines containing 50 jg PPD 50 pg 3D-MLA/AF. 3D-MLA/AF was prepared as in Example 1. Spleen cells were harvested 14 days after immunization and used as a source of lymphocytes in a proliferation assay. The spleen cells were cultured for 96 hr in microtiter wells at a concentration of 106 cells/ml in media containing 0.1, 1 or gg PPD/ml. Tritiated thymidine was added to the cultures during the final 24 hr of incubation. The cells were harvested on glass fiber filters and tritium incorporation was determined. Stimulation indices were determined by dividing counts per minute (CPM) of cells stimulated with PPD by the CPM of cells cultured in media alone. The resulting data are shown in Figure 2.

WO 98/43670 PCTIUS98/06528 Example 4-Stimulation of a Cvtotoxic T-lymphocvte Response.

The induction of a cytotoxic T-lymphocyte response after administration of the aqueous adjuvant composition of the subject invention and a protein antigen was detected by a cytotoxicity assay. Groups of C57/BL/6 mice were given a primary immunization subcutaneously (inguinal region) with 25 gg ovalbumin (OVA) formulated in 3D-MLA/AF. 3D-MLA/AF was prepared as in Example 1. The injected volume was 200 tl. Twenty-one days later three mice per experimental group were killed and spleens removed and pooled as single cell suspensions and counted.

Spleen cells (75 X 106 cells in 3-4 ml media) from the experimental groups were placed in a 25 cm 2 T-flask. Next, 1.0 ml of irradiated (20,000 rads) E.G7 (OVA) cells at 5 X 10'/ml were added to the flask. The volume was brought to 10 ml. The cultures were maintained by placing the T-flasks upright in a 37C, 5% CO 2 incubator for four days. On day 4 the surviving cells were recovered from the flasks, washed 1X, resuspended in 5.0 ml, and counted.

15 Recovered effector cells were adjusted to 5 X 106 viable cells/ml and 100 il volumes were diluted serially in triplicate in wells of 96 well round-bottom plates (Coming 25850) using 100 tl/well of media as a diluent. Next, 100 il volumes of "Cr-labelled (see below) targets [E.G7 (OVA)-an ovalbumin gene transfected EL-4 cell line] at 1 X 10 s cells/ml were added to the wells. Spontaneous release (SR) wells S 20 contained 100 tl of targets and 100 pl of media. Maximal release (MR) wells contained 100 ul of targets and 100 ul detergent Tween 20). Effector/target ratios were 50:1, 25:1, 12.5:1, 6.25:1. The plates were centrifuged at 400 Xg and incubated at 37C, 5% CO, for 4 hr. After the incubation the well supernatants were collected using a Skatron Supernatant Collection System.

Percent specific lysis= 100 X (Exp.Release

SR)

R SR) Target cells, E.G7 (OVA), were labelled with "Cr (sodium chromate) as follows. In a total volume of 1.0 ml were mixed 5 X 106 target cells and 250 pCi SCr SWO 98/43670 PCT/US98/06528 11 in 15 ml conical tube. The cell suspensions was incubated in a 37"C water bath for min., with gentle mixing every 15 min. After incubation the labelled cells were washed 3X by centrifugation and decanting with 15 ml volumes of media. After the third centrifugation the cells were resuspended in 10 ml of fresh media and allowed to stand at room temperature for 30 min. and then centrifuged. The cells were finally resuspended in media to 1 X 10' cells/ml. The results of the cytotoxicity assay, are presented in Table 1.

Table 1 Cytotoxicity (S'Cr-release) Effector: Target Ratio Material 50:1 25:1 12.5:1 6.25:1 PBS* 13 10 7 2 3D-MLA/AF 61 60 59 Non-immune spleen cells 8 4 2 2 *phosphate buffered saline Example 5-Stimulation of an Antibody Response by Intranasal Administration of the Aqueous ALD formulation.

Mice administered tetanus-toxoid (TT) in 3D-MLA/AF intranasally produced 20 IgA titers detectable in both serum and fecal extracts. Further, intranasal administration of the aqueous formulation of the subject invention and TT produced Shigh titers of the IgG isotypes IgG2 and IgG2b.

Groups ofICR mice were given intranasally, 0.5, 2.5, 10 or 12.5 jg tetanus i. toxoid in phosphate buffered saline (PBS) or admixed with 25 ig 3D-MLA/AF. 3D- MLA/AF was prepared as in Example 1. Mice were primed on day 0, bled on day (dlOPI boosted on day 14, bled on day 24 (d10P2 0 boosted on day 28, bled on day 38 (dl0P3 ELISA for IgG- and IgA specific anti-tetanus toxoid antibody was done on pooled sera from each bleed. Fecal extracts were examined on day 22 (d7P2 IgG and IgA titers of sera and fecal extracts of immunized mice are shown in Tables .1 000 0: 0. Table 2 Serum Anti-Tetanus Toxoid Tite T Q ;r.

5 9~ Vaccine* pg TT +PBS pg T1+ PBS 12.5 pg PBS pg TI 3D-MLA/AF pg TT+ 3D-AMLA/AF 12.5pg TT 3D-MLA/AF Route

IN

IN

IN

IN

IN

IN

dl OP 10 200 400 3,200 12,800 51,200 102,400 dl I0P2 0 400 51,200 51,200 >409,600 >409,600 >409,600 204,800 dl0P3 0 25,600 25,600 102,400 >409,600 >409,600 >409,600 409,600 dl OP 10 <200 <200 <200 <200 <200 <200 IRA-S Decific d] 0P2 0 <200 <200 200 800 12,800 25,600 dl 0P3 0 <200 <200 400 6,400 25,600 102,400 pg TT PBS <200 <200 <200 *n=4 WO 98/43670 PTU9/62 PCT/US99/06528 13 Table 3 IgG Isotype Analysis of Serum from d I0P3 Bleeds in Table 2.

Anti-Tetanus Toxoid Titer' Vaccine Route IgG, IgG2. IgG 2 b p.g TT PBS IN 25,600 6,400 25,600 2.5 ig TT +PBS IN 51,200 3,200 25,600 12.5 pg TT +PBS IN 204,800 12,800 51,200 gg TT 3D-MLA/AF IN 819,200 409,600 819,200 pg TT +3D-vLAJAIF IN >819,200 819,200 >819,200 12.5gTT +3D-MLAAF IN >819,200 >819,200 >819,200 pg Tir PBS SQ 819,200 6,400 25,600 Normal Mouse Sera <400 <400 <400 Vaccine Tr* 3D-MIA/AF/PBS TT DPPC/PBS TT 3D-MILAIAFIPBS Normal Mouse Sera Route

IN

IN

SQ

Table 4 Serum Anti-Tetanus Toxoid Titer' IgG-Specific IgA-Speciic d1OP2 0 dIOP3 0 dIOP2* d1OP3 0 >102,400 >102,400 6,400 25,600 6,400 6,400 100 200 102,400 >102,400 100 100 50 50 100 100 Fecal Extract d7P2- IgG IgA <50 1,600 <50 <50 <50 pg of te(anus toxoid were administered WO 98/43670 PCT/US98/06528 Table IgG Isotype Analysis of Serum from dl 0P3 Bleeds in Table 4.

Anti-Tetanus Toxoid Titers-' Vaccine Route IgG, IgG2, IgG2b TT 3D-MLA/AF/PBS IN >819,200 102,400 409,600 TT DPPC/PBS IN 25,600 1,600 3,200 TT 3D-MLA/AF/PBS SQ >819,200 51,200 102,400 Normal Mouse Sera <400 <400 <400 Example 6-Stimulation of an Immune Response to Hepatitis B Surface Antigen by Intranasal Administration of the Aqueous ALD Formulation.

Mice administered hepatitis B surface antigen (HBSAG) in the composition of the subject invention intranasally produced serum IgG and IgA titers to that antigen.

15 Secretory IgA was detected in vaginal washes and the induction of a cytotoxic Tlymphocyte response was detected by a cytotoxicity assay.

Groups of Balb/C mice were given a primary immunization intranasally :with 2.5 gg HBsAg 10 gg 3D-MLA/AF in a volume of 20 ul. 3D-MLA/AF was prepared as in Example 1. Twenty-one days later mice were given a secondary immunization of 7.5 pg HBsAg 10 gg 3D-MLA/AF intranasally in 20 pl. A tertiary immunization (3 identical in composition to the secondary immunization was administered 28 days after the secondary immunization. Assays were conducted to o. detect cytotoxic T-lymphocyte activity at 16 days post secondary immunization (dl6,post 20) and 8 days post tertiary immunization (d8, post 30). Serum and mucosal antibody titers were assessed at 22 days post secondary immunization (d22, post 2°) and 21 days post tertiary immunization (d21, post 3 All assays were conducted by methods standard in the art and described in previous Examples 2 and 4. Results from this experiment are shown in Tables 6-8.

WO 99/43670 WO98/4670PCTIUS98/06528 16 Table 6 Material 3D-MAAF Vehicle Non-immune spleen cells Day d16, post 20 Cytotoxicity 51 Cr-release) Effector: Target Ratio 50:1 25:1 12.5:1 6.25:1 38 22 15 9 3 2 0 0 3 3 0 0 3D-MILA/AF Vehicle d8, post Non-immune spleen cells Table 7 Material 3D-MLA/AF Vehicle 3D-M4LA/AF Vehicle Day d22, post 20 Anti IfBsA%! Titer' IgG, IgG 2 256,000 64,000 <2,000 <2,000 IgA 1,600 <200 25,600 <200 El' d2 1, post 30* 1,000,000 <2,000 1,000,000 <2,000 Groups of Balb/C mice were immunized with 2.5 g'g HBsAg 10 jgg 3D- MLA/AF intranasally and boosted intranasally with 7.5 .ig HBsAg 10 jag 3D- MVLA/AF 21 days later. Vaginal samples were collected 10 days after the booster immunization.

-WO 98/43670 PCT/US98/06528 17 Table 8 Vaginal Wash Anti-HBSAG Titer-' Material Ig IA 3D-MLA/AF 100 6400 Vehicle <50 The intranasal administration of HBsAg in the composition of the subject invention stimulated both a humoral and cellular immune response to that antigen.

Intranasal immunization with the antigen formulated in 3D-MLA/AF induced a cytotoxic T-lymphocyte response and antigen specific humoral and mucosal immune responses.

Example 7-Generation of a Protective Immune Response to Influenza by Intranasal S: Administration of the Aqueous ALD Formulation.

Mice immunized intranasally with FLUSHELD influenza vaccine containing 20 hemagglutinin antigen formulated in the composition of the subject invention produced both IgG and IgA which were recovered in vaginal washes. Immunized mice were also protected 100% from subsequent influenza challenge.

ICR mice were immunized three times at 21 day intervals intranasally with FLUSHIELD influenza vaccine (Wyeth-Lederle) containing 0.3 lg hemagglutinin 25 antigen (HA) 10 gg 3D-MLA/AF. 3D-MLA/AF was prepared as in Example 1.

Vaginal washes were collected 14 days after the final immunization. Mice were challenged with 10 LDs, (lethal dose 50) of infectious influenza A/HK/68 thirty-five days after the final immunization and monitored for mortality.

I WO 99/43670 PCT/US98/06528 18 Table 9 Group Nonimmune Vehicle 3D-MLA/AF IgA Vaginal Wash <20 160 2560 IgG Vaginal Wash <20 80 1280 Protection 0 100 Example 8-Compositions of Monophosphoryl Lipid A.

Monophosphoryl lipid A (MLA) can be formulated into the aqueous compositions of the subject invention and administered in the same quantities and amounts as in Examples 1-7 to produce similar results.

It is understood that the foregoing examples are merely illustrative of the present invention. Certain modifications of the compositions and/or methods employed may be made and still achieve the objectives of the inventions. Such modifications are contemplated as within the scope of the claimed invention.

r r r

Claims (6)

1. A dry formulation of an immunostimulatory adjuvant, said formulation comprising: an immunostimulatory adjuvant which is a member selected from monophosphoryl lipid A, 3-O-deacylated monophosphoryl lipid A and combinations thereof; a non-immunostimulatory surfactant; and a glycerol in an amount sufficient to provide a clear suspension of particles of said immunostimulatory adjuvant upon contacting said formulation 10 with water without sonication.

2. The formulation according to claim 1, wherein said glycerol is a member selected from the group consisting of poly(propylene glycol) and poly(ethylene glycol), and combinations thereof.

3. The formulation according to claim 1, wherein said particles are from about 40 nm to about 150 nm in size.

4. The formulation according to claim 3, wherein said particles are from about 50 nm to about 70 nm in size.

5. The formulation according to claim 1, wherein said non- immunostimulatory surfactant is 1,2-dipalmitoyl-sn-glycero-3-phosphocholine.

6. A dry formulation of an immunostimulatory adjuvant said formulation substantially as herein described.